Collaboration for wound care treatment

You are here

Home    /    Collaboration for wound care treatment

Lyon, Cleveland, June 27th, 2017 - AMOEBA announced today the development of a collaboration with VISCUS BIOLOGICS in order to carry out collective testing on a new wound care application in the field of human health.

VISCUS BIOLOGICS has a proven expertise in the field of wound care products, in particular collagen-based dressings. Following preliminary in vitro testing, the two companies intend to extend their cooperation and further confirm, through additional in vitro and in vivo testing, the action of the Willaertia magna C2c Maky micro-organism against certain pathogenic Multi-Drug Resistant (MDR) bacteria that resist multiple antibiotics.  Willaertia magna C2c Maky could therefore be used with advanced wound care dressings. This project is in the first instance focusing on the US market.

In a global advanced wound care market estimated at USD 17 billion1, the antimicrobial dressing segment represents USD 1.87 billion2 with a potential CAGR of USD 841 million3 in the USA.

« With this project with AMOEBA, VISCUS BIOLOGICS is aiming to address a very important market segment in the wound care industry.  Ultimately, Willaertia magna C2c Maky on its own or in combination with other treatments may provide another tool for treating wounds that are infected or at risk of becoming infected. » stated Peter GINGRAS, CEO of VISCUS BIOLOGICS.

« With this collaboration with VISCUS BIOLOGICS, AMOEBA is reaching an historical turning point in its development. We will be able to contribute to the advancement of clinical research to meet the global challenge of bacterial resistance to antibiotics (chemical molecules). Preliminary in vitro testing supports the use of Willaertia Magna C2c Maky on antibiotic-resistant strains. This partnership opens new development perspectives for AMOEBA beyond water treatment, in the chronic wound care market. » added Fabrice PLASSON, CEO of AMOEBA.

Related Posts

10
Jul

Success of Amoéba’s initial public offering

News
0 comments

Lyon, 10 July 2015 - Amoéba successfully accomplished its initial public offering for trading of its shares on the regulated Euronext exchange in Paris (Compartment C). Despite a particularly unfavourable market context, Amoéba managed to raise around 13.2 million Euros from institutional and private investors. The price of the offering was set at 8.30€ per share. Following the ceremony for the initial public offering, trading started on 10 July 2015.

11
Jun

Amoéba enters the Canadian market

News
0 comments

Lyon, Montreal 3 June 2015 - Amoéba signed a letter of intent for the whole of Canada with the Magnus group. Recognised as a leader in green chemistry, since 1946 the MAGNUS group has been instrumental in setting up a range of water treatment programmes for industrial, institutional and commercial applications. This letter of intent was signed in preparation for an agreement relating to the exclusive distribution of AMOEBA’s product by the MAGNUS group for a 5-year period, provided that market authorisation (MA) is obtained for Canada, expected at the end of 2017.

 

11
Mar

Amoéba communication 2.0

News
0 comments

Constantly evolving since its creation, Amoéba has just passed a very symbolic milestone: the creation of a new visual identity, based on a modern, dynamic website, just like the company it represents. So, Amoéba is now in the 2.0 age with 2.0 communication tools.

Pages